HPV self-collection: The test is only the beginning

HPV self-collection may be one of the most promising advances in cervical cancer screening in decades. But before we embrace the convenience of collecting a vaginal swab at home, we should ask a harder question: What happens when the result comes back positive?

The technology itself is promising. The molecular assay demonstrates high sensitivity for detecting high-risk HPV and cervical precancers, with performance approaching that of clinician-collected samples. The question is no longer simply whether the technology works. It is where – and how – we should use it.

We are particularly interested in its potential for rural communities. Screening in a clinic can mean taking time off work, arranging transportation and childcare, and traveling significant distances for a preventive test. Self-collection could remove that geographic barrier. It can also expand access for patients for whom a pelvic examination presents unique challenges: patients who cannot tolerate an exam, with a history of sexual trauma, gender diverse identity or who request a female clinician when one is not available.

But our experience has made us think about another side of the equation. Self-collection may help but only if the system is prepared for what comes next.

Someone still needs to communicate the result, to explain what an HPV-positive result means and ensure that patients who require additional evaluation receive it. Health systems need a mechanism to connect patients with diagnostic evaluation, including clinician-collected testing, colposcopy, biopsy and treatment when indicated. Otherwise, we risk creating a system that identifies risk well but is poorly equipped to address it. Emerging technologies, including artificial intelligence tools, could help clinicians communicate routine results and track follow-up without replacing clinical judgment.

There are also important limitations. HPV self-collection is a screening tool, not a replacement for gynecologic care. Not all cervical pathology is caused by HPV, meaning HPV self-collection cannot identify every possible cervical abnormality. And patients still need care for contraception, sexual health, abnormal bleeding, menopause and other gynecologic concerns.

The goal should not be to eliminate the gynecologic visit. It should be to eliminate unnecessary barriers to screening.

We are excited by where this technology could go next. Imagine a single vaginal swab capable of testing for HPV alongside other conditions, such as chlamydia, gonorrhea, trichomoniasis and bacterial vaginosis. Pair that with telemedicine, and the possibilities become even more interesting: a patient could complete a virtual visit, receive a collection kit, send in a sample and receive appropriate follow-up all while avoiding a trip to the office.

But innovation requires infrastructure. Providers need to trust the technology. Patients need clear communication. Insurers need to cover it. And health systems need reliable pathways to diagnostic evaluation and treatment. This raises what we think is the most important ethical question surrounding HPV self-collection: Is it ethical to offer a screening test when you cannot provide the care required for patients with abnormal results?

The future of femtech should not be about moving healthcare out of the doctor’s office at all costs. It should be about knowing which parts of care truly require a visit – and using technology to make everything else more accessible, without losing the human connection when patients need it most.

By Drs. Rabab Isa, a third-year medical resident; Anthony Costales, assistant professor in the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, and Claire Hoppenot, assistant professor in the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine and affiliated faculty at the Center for Medical Ethics and Health Policy